IMGN901 in Combination With Lenalidomide and Dexamethasone

ClinicalTrials.gov ID: NCT00991562

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00991562. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to test IMGN901 in combination with lenalidomide and dexamethasone every 28 days.

Study identification

NCT ID: NCT00991562
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: ImmunoGen, Inc.; Industry
Enrollment: 50 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

IMGN901 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2009 (Type not available)
Primary completion: Aug 2013 (Actual)
Completion: Oct 2014 (Actual)
Last update posted: Nov 21, 2014

2009 – 2014

United States locations

U.S. sites: 9
U.S. states: 7
U.S. cities: 9

Facility	City	State	ZIP	Site status
University of Southern California	Los Angeles	California	90033	—
Comprehensive Cancer Center of the Desert	Palm Springs	California	92262	—
Florida Cancer Specialists	Sarasota	Florida	34232	—
Roswell Park Cancer Institute	Buffalo	New York	14263	—
Weill Medical College	New York	New York	10021	—
Duke University Medical Center	Durham	North Carolina	27710	—
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	—
Sarah Cannon Research Institute	Nashville	Tennessee	37203	—
CTRC at University of Texas Health Science Center	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00991562, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 21, 2014 · Synced Nov 14, 2026